

溶瘤麻疹病毒抗肿瘤治疗“瓶颈”与破解对策

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年07期 页码: 1252-1255 栏目: 综述 出版日期: 2019-02-28

Title: Challenges and strategies of oncolytic measles virus

作者: 夏茂; 陈军浩

南京鼓楼医院检验科, 江苏 南京 210007

Author(s): Xia Mao; Chen Junhao

Deptment of Clinical Lab, Nanjing Drum Tower Hospital, Jiangsu Nanjing 210007, China.

关键词: 溶瘤病毒; 溶瘤麻疹病毒; 瓶颈; 对策

Keywords: oncolytic virus; oncolytic measles virus; challenge; strategy

分类号: R730.5

DOI: 10.3969/j.issn.1672-4992.2019.07.039

文献标识码: A

摘要: 在肿瘤基因治疗领域, 具有自我复制、能选择性杀伤肿瘤的溶瘤病毒已成为抗肿瘤治疗的有效武器之一。其中溶瘤麻疹病毒因其拥有极好的安全记录和优秀的抗癌效果目前已经进入多项临床试验阶段。但是仍存在一些因素会影响溶瘤麻疹病毒成功治疗肿瘤, 研究者们正在努力寻找对策以期破解这些瓶颈, 使溶瘤麻疹病毒更好的发挥溶瘤作用。

Abstract: Replication-competent oncolytic viruses selectively infect and kill malignant cells, which have been proved as potent anticancer weapon in clinical therapy. Due to its excellent safety records and therapeutic efficacy, oncolytic measles virus has been investigated in several clinical trials to treat advanced cancer patients. However, there are some challenges for oncolytic measles viruses limit their oncolytic efficacy in cancer therapy. Many studies provide theoretical basis and/or novel strategies for oncolytic viral therapy against malignancies.

参考文献/REFERENCES

- [1] Bartlett DL, Liu Z, Sathiah M, et al. Oncolytic viruses as therapeutic cancer vaccines [J]. *Mol Cancer*, 2013, 12(1): 103.
- [2] Russell L, KW Peng. The emerging role of oncolytic virus therapy against cancer [J]. *Chin Clin Oncol*, 2018, 7(2): 16.
- [3] Lech PJ, SJ Russell. Use of attenuated paramyxoviruses for cancer therapy [J]. *Expert Rev Vaccines*, 2010, 9(11): 1275-1302.
- [4] Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview [J]. *Curr Opin Mol Ther*, 2009, 11(1): 43-53.
- [5] Bhattacharjee S, Yadava PK. Measles virus: Background and oncolytic virotherapy [J]. *Biochem Biophys Rep*, 2018, 13: 58-62.
- [6] Parrula C, Fernandez SA, Zimmerman B, et al. Measles virotherapy in a mouse model of adult T-cell leukaemia/lymphoma [J]. *J Gen Virol*, 2011, 92(Pt 6): 145814-145866.
- [7] Dispenzieri A, Tong C, LaPlant B, et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma [J]. *Leukemia*, 2017, 31(12): 2791-2798.
- [8] Penheiter AR, Wegman TR, Classic KL, et al. Sodium iodide symporter(NIS)-mediated radiovirotherapy for pancreatic cancer [J]. *AJR Am J Roentgenol*, 2010, 195(2): 341-349.
- [9] Allen C, Opyrchal M, Aderca I, et al. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells [J]. *Gene Ther*, 2013, 20(4): 444-449.
- [10] Hartkopf AD, Bossow S, Lampe J, et al. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase [J]. *Gynecol Oncol*, 2013, 130(2): 362-368.
- [11] Msaouel P, Iankov ID, Allen C, et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer [J]. *Prostate*, 2009, 69(1): 82-91.
- [12] Iankov ID, Msaouel P, Allen C, et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model [J]. *Breast Cancer Res Treat*, 2010, 122(3): 745-754.

- [13] Donnelly OG, Errington-Mais F, Steele L, et al. Measles virus causes immunogenic cell death in human melanoma [J]. *Gene Ther*, 2013, 20(1): 7-15.
- [14] Allagui F, Achard C, Panterne C, et al. Modulation of the type I interferon response defines the sensitivity of human melanoma cells to oncolytic measles virus [J]. *Curr Gene Ther*, 2017, 16(6): 419-428.
- [15] Meng X, Nakamura T, Okazaki T, et al. Enhanced antitumor effects of an engineered measles virus edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma [J]. *Mol Ther*, 2010, 18(3): 544-551.
- [16] Jacobson BA, Sadiq AA, Tang S, et al. Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma [J]. *Oncotarget*, 2017, 8(38): 63096-63109.
- [17] Studebaker AW, Kreofsky CR, Pierson CR, et al. Treatment of medulloblastoma with a modified measles virus [J]. *Neuro Oncol*, 2010, 12(10): 1034-1042.
- [18] Boisgerault N, Guillerma JB, Pouliquen D, et al. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas [J]. *Biomed Res Int*, 2013, 2013: 387362.
- [19] Reddi HV, Madde P, McDonough SJ, et al. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy [J]. *Cancer Gene Ther*, 2012, 19(9): 659-665.
- [20] Bucheit AD, Kumar S, Grote DM, et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen [J]. *Mol Ther*, 2003, 7(1): 62-72.
- [21] Grunwald GK, Klutz K, Willhauck MJ, et al. Sodium iodide symporter(NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus [J]. *Gene Ther*, 2013, 20(6): 625-633.
- [22] Zhang SC, Wang WL, Cai WS, et al. Engineered measles virus edmonston strain used as a novel oncolytic viral system against human hepatoblastoma [J]. *BMC Cancer*, 2012, 12: 427.
- [23] Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy [J]. *Nat Biotechnol*, 2012, 30(7): 658-670.
- [24] Russell SJ, Federspiel MJ, Peng KW, et al. Remission of disseminated cancer after systemic oncolytic virotherapy [J]. *Mayo Clin Proc*, 2014, 89(7): 926-933.
- [25] Mader EK, Meayama Y, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model [J]. *Clin Cancer Res*, 2009, 15(23): 7246-7255.
- [26] Audet S, Virata-Theimer ML, Beeler JA, et al. Measles-virus-neutralizing antibodies in intravenous immunoglobulins [J]. *J Infect Dis*, 2006, 194(6): 781-819.
- [27] Fisher K. Striking out at disseminated metastases: The systemic delivery of oncolytic viruses [J]. *Curr Opin Mol Ther*, 2006, 8(4): 301-313.
- [28] Jain RK, Stylianopoulos. Delivering nanomedicine to solid tumors [J]. *Nat Rev Clin Oncol*, 2010, 7(11): 653-664.
- [29] Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses [J]. *Nat Med*, 1999, 5(8): 881-887.
- [30] Russell SJ, Peng KW. Measles virus for cancer therapy [J]. *Curr Top Microbiol Immunol*, 2009, 330: 213-241.
- [31] Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice [J]. *Blood*, 2006, 107(5): 1810-1817.
- [32] Marelli G, Howells A, Lemoine NR, et al. Oncolytic viral therapy and the immune system: A double-edged sword against cancer [J]. *Front Immunol*, 2018, 9: 866.
- [33] Munguia A, Ota T, Miest T, et al. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth [J]. *Gene Ther*, 2008, 15(10): 797-806.
- [34] Iankov ID, Blehacz B, Liu C, et al. Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy [J]. *Mol Ther*, 2007, 15(1): 114-122.
- [35] Ong HT, Hasegawa K, Dietz AB, et al. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies [J]. *Gene Ther*, 2007, 14(4): 324-333.
- [36] Wei J, Jarmy G, Genuneit J, et al. Human blood late outgrowth endothelial cells for gene therapy of cancer: Determinants of efficacy [J]. *Gene Ther*, 2007, 14(4): 344-356.
- [37] Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers [J]. *Mol Ther*, 2010, 18(6): 1155-1164.
- [38] Winkelstein A. Mechanisms of immunosuppression: Effects of cyclophosphamide on cellular immunity [J]. *Blood*, 1973, 41(2): 273-284.
- [39] Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide [J]. *Clin Pharmacol Ther*, 2007, 82(6): 700-710.
- [40] Driessen WH, Ozawa MG, Arap W, et al. Ligand-directed cancer gene therapy to angiogenic vasculature [J]. *Adv Genet*, 2009, 67: 103-121.
- [41] Thorne SH, Hwang TH, O'Gorman WE, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963 [J]. *J Clin Invest*, 2007, 117(11): 3350-3358.
- [42] Lal SC, Raffel. Using cystine knot proteins as a novel approach to retarget oncolytic measles virus [J]. *Mol Ther Oncolytics*, 2017, 7: 57-66.
- [43] Kleinlutzum D, Hanauer JDS, Muik A, et al. Enhancing the oncolytic activity of cd133-targeted measles virus: Receptor extension or chimerism with vesicular stomatitis virus are most effective [J]. *Front Oncol*,

2017, 7: 127.

[44] Ong HT, Trejo TR, Pham LD, et al. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo [J]. *Mol Ther*, 2009, 17(6): 101210-101221.

备注/Memo: National Natural Science Foundation of China (No.81602702) ;国家自然科学基金青年项目 (编号: 81602702) ; 江苏省自然科学基金青年项目 (编号: BK20160126) ; 江苏省卫生计生委青年科研课题项目 (编号: Q201613)

更新日期/Last Update: 2019-02-28